Quince Therapeutics Inc (QNCX) Stock Price, Quote & News

Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an aut...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 910 5717

Website: www.quincetx.com

Address:

611 Gateway Boulevard, Suite 273, South San Francisco, United States

kb60521 Feb. 5 at 10:24 PM

$QNCX if the understanding of all the call options and put options are sold by MMs is true, then for this Feb 20th are MMs going to buy approximately 1.5 million of QNCX shares at $1500000 2.50? anyone has any idea? Please share....

0 · Reply

Invest_to_grow Feb. 5 at 8:25 AM

$QNCX Overnight looking good! Looks like something is up!

1 · Reply

Richard12_ Feb. 4 at 11:14 PM

$ELPW $INHD $JTAI $LIMN $QNCX $JTAI NO PUMP N DUMPS! lONG TERM HOLD HERE!

0 · Reply

RD008 Feb. 4 at 11:12 PM

$ELPW $JTAI $QNCX $LIMN $INHD

0 · Reply

AnchoredWealth Feb. 4 at 9:12 PM

$QNCX Any news or just a rebound from oversold levels?

0 · Reply

BullishBanana Feb. 4 at 4:09 PM

$QNCX Post-NEAT failure, QNCX may pursue a DMD licensing deal similar to their Lighthouse Pharma play: ☑ Partner funds Phase 1, 2 & NDA → QNCX avoids burn/dilution ☑ Upfront + milestones + royalties → risk-adjusted PPS ~ $1.8 pre-commercial ☑ Platform ownership retained → downside capped even if trials fail ☑ Phase 3 success by partner → optional acquisition / further upside (~$2–$3 PPS potential) This could instantly revalue the stock, especially with extreme short interest. Retail + institutions likely underappreciate this optionality.

0 · Reply

BullishBanana Feb. 4 at 11:12 AM

$QNCX It is likely that companies such as Sanofi or Novartis already have extensive experience with DMD trials. One could speculate that the board may have had a strategic focus on DMD from the outset. The Ataxia-Telangiectasia (A-T) trials, by contrast, were conducted in partnership with EryDel because the company did not have sufficient capital to fund them independently. With EryDel no longer involved, the board can now concentrate on conditions where corticosteroid-based treatments are known to be effective. It is also possible that the board was already in discussions with a potential partner or acquirer to oversee the DMD trials even prior to the NEAT Phase 3 readout. (part 1)

3 · Reply

Mario789 Feb. 4 at 10:37 AM

$ELPW $INHD $JTAI $LIMN $QNCX ok reported for spamming

0 · Reply

Kesiya Feb. 4 at 10:36 AM

TOP 5 Stocks with High Potential for Upward Movement During/ premarket Update! 1.$ELPW Float :3.18M Float & OS:3.18M / 6.23M Fee 201.48% Zero Borrow 2.$JTAI Float & OS:45.44M / 45.48M Fee 24.34% 3.$QNCX Float & OS:47.75M / 55.68M 4.$LIMN Float & OS:8.85M Fee 41.32% 5.$INHD Float & OS:5.37M / 8.41M Fee 49.56% 49.56% 40,000

0 · Reply

TheSharks Feb. 3 at 8:58 PM

$QNCX it's down another 50% from it's original crash point....I'm in at .20. I still think we see .30s within a couple of weeks. Entry here is a gift.

0 · Reply

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Jan 28, 2026, 4:05 PM EST - 8 days ago

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Jan 12, 2026, 11:08 AM EST - 24 days ago

Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential

Dec 15, 2025, 8:00 AM EST - 7 weeks ago

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

Dec 10, 2025, 4:05 PM EST - 2 months ago

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

Nov 24, 2025, 8:00 AM EST - 2 months ago

Quince Therapeutics to Participate at Investor Events in December 2025

Nov 12, 2025, 4:05 PM EST - 3 months ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 4:05 PM EST - 3 months ago

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Oct 9, 2025, 4:05 PM EDT - 4 months ago

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Oct 2, 2025, 5:12 PM EDT - 4 months ago

Quince Therapeutics, Inc. (QNCX) Analyst/Investor Day Transcript

Sep 25, 2025, 4:05 PM EDT - 4 months ago

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Sep 24, 2025, 1:13 AM EDT - 4 months ago

Quince Therapeutics, Inc. - Special Call

Sep 11, 2025, 4:05 PM EDT - 5 months ago

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Sep 2, 2025, 4:05 PM EDT - 5 months ago

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 11, 2025, 4:05 PM EDT - 6 months ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:00 AM EDT - 6 months ago

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

OPCH

Jul 16, 2025, 8:00 AM EDT - 7 months ago

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jul 10, 2025, 4:05 PM EDT - 7 months ago

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Jun 25, 2025, 4:05 PM EDT - 8 months ago

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Jun 18, 2025, 4:05 PM EDT - 8 months ago

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Jun 12, 2025, 5:15 PM EDT - 8 months ago

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Jun 3, 2025, 4:05 PM EDT - 8 months ago

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

May 15, 2025, 9:50 AM EDT - 9 months ago

Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

May 13, 2025, 8:00 AM EDT - 9 months ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 10 months ago

Quince Therapeutics to Present at Citizens Life Sciences Conference

Apr 3, 2025, 4:05 PM EDT - 11 months ago

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 4:05 PM EDT - 11 months ago

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Feb 7, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Feb 5, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Jan 28, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Jan 27, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Jan 23, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Nov 13, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Nov 11, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Oct 14, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Participate at Upcoming Investor Conferences

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 9:16 PM EDT - 1 year ago

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

May 13, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 6, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Feb 22, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Launches Scientific Advisory Board

Feb 15, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Feb 7, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 4, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Participate at Investor Events in January 2024

kb60521 Feb. 5 at 10:24 PM

0 · Reply

Invest_to_grow Feb. 5 at 8:25 AM

$QNCX Overnight looking good! Looks like something is up!

1 · Reply

Richard12_ Feb. 4 at 11:14 PM

$ELPW $INHD $JTAI $LIMN $QNCX $JTAI NO PUMP N DUMPS! lONG TERM HOLD HERE!

0 · Reply

RD008 Feb. 4 at 11:12 PM

$ELPW $JTAI $QNCX $LIMN $INHD

0 · Reply

AnchoredWealth Feb. 4 at 9:12 PM

$QNCX Any news or just a rebound from oversold levels?

0 · Reply

BullishBanana Feb. 4 at 4:09 PM

0 · Reply

BullishBanana Feb. 4 at 11:12 AM

3 · Reply

Mario789 Feb. 4 at 10:37 AM

$ELPW $INHD $JTAI $LIMN $QNCX ok reported for spamming

0 · Reply

Kesiya Feb. 4 at 10:36 AM

0 · Reply

TheSharks Feb. 3 at 8:58 PM

$QNCX it's down another 50% from it's original crash point....I'm in at .20. I still think we see .30s within a couple of weeks. Entry here is a gift.

0 · Reply

Sly1939 Feb. 3 at 8:57 PM

$QNCX added more. 1450. Finished

0 · Reply

AnchoredWealth Feb. 3 at 8:53 PM

$QNCX okayyy, where’s the bottom?😀

0 · Reply

Sly1939 Feb. 3 at 8:25 PM

$QNCX Re-entered. 1529. Bids sitting lower

0 · Reply

CheckingMorons Feb. 3 at 7:13 PM

$QNCX 30k more added tight SL

0 · Reply

Trade_the_plan Feb. 3 at 4:59 PM

$QNCX not a Lucid Capital but Loser Capital. Pumping pt of $8 and now sell rating. Losers

0 · Reply

CheckingMorons Feb. 3 at 4:27 PM

$QNCX very bearish here Max 1 week hold scalping to 0.19-0.20 . Buying another 50k at 0.01550 and 30k k at 0.1510 if it gets there

0 · Reply

CheckingMorons Feb. 3 at 3:55 PM

$QNCX ok I got really bored waiting for lower 30k shares bough SL 0.138 might buy 20k more at 0.1510 ish

0 · Reply

silentmaxx Feb. 3 at 3:12 PM

$QNCX

0 · Reply

kb60521 Feb. 3 at 2:52 PM

$QNCX OMG....has anyone noticed the Feb 20th 2.50 Put open interest. Can't imagine someone forced to buying this at 2.50.....

1 · Reply

Bull711 Feb. 3 at 2:46 PM

$QNCX Testing a few at this level.

0 · Reply

ParagonStar1 Feb. 3 at 11:49 AM

$QNCX Clinical progress / FDA paths. Success in trials or accelerated approvals can radically re-rate a biotech stock.

1 · Reply

PLATINUM_TRADES Feb. 3 at 10:35 AM

$QNCX Tiny little penny I took $.17 for fun... $.20's next? 🤔 🤔

0 · Reply

Market Cap	8.10M
Revenue (ttm)	0.00
Net Income (ttm)	-56.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	16.53

Volume	3,999,500
Avg Vol	2,612,002
Day's Range	N/A - N/A
Shares Out	55.68M
Stochastic %K	1%
Beta	1.22
Analysts	Hold
Price Target	$7.67